BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, June 5, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 3, 2011
View Archived Issues
Selective SYK inhibitors P505-15 and P459-72 show anticancer potential
Read More
Anti-HIV-1 activity of aciclovir and potentiation by ribavirin
Read More
Tekmira Pharma begins phase I trial of TKM-080301 in solid tumors
Read More
New antagonists of melanin-concentrating hormone MCH1 receptor claimed
Read More
Apricus Biosciences grants Bracco rights to market Vitaros in Italy
Read More
New CGRP receptor antagonists identified by Boehringer Ingelheim
Read More
Phase II trial evaluates CK-2017357 in generalized myasthenia gravis
Read More
New antagonists of voltage-gated potassium channels claimed by Xention
Read More
FDA approves generic version of Doryx
Read More
Vascular Biogenics begins phase II trials of VB-111 in glioblastoma and thyroid cancer
Read More
Novartis researchers claim novel PI3K and mTOR inhibitors
Read More
BioCryst Pharma begins phase IIb trial of BCX-4208 as add-on therapy for gout
Read More
Advanced Cell Technology enters stock purchase agreement with Socius
Read More
BioSante raises funds for phase III LibiGel program
Read More
Phase II data presented on AIC-246 for human cytomegalovirus infection
Read More
Cumberland Pharma voluntarily recalls six lots of Acetadote in U.S.
Read More
IMMU-114 shows potential for treating GVHD
Read More
Lundbeck completes two phase III trials of nalmefene for alcohol dependence
Read More
McKesson acquires US Oncology
Read More
BL-5010 is efficacious in nonsurgical removal of skin lesions in phase I/II trial
Read More
Proteome Sciences and Janssen Pharmaceutica enter into collaboration
Read More
MK-2461 is active in model of multiple myeloma
Read More
